Physician profile
Wenge Lu
NPI 1174867378
$15,167.76
in general payments reported to CMS, 2019-2025
60 companies · $2,740 in 2025
The $2,740 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $952 · 2021: $1,865 · 2022: $2,555 · 2023: $2,785 · 2024: $3,683 · 2025: $2,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,485 · Travel and Lodging: $687 · Education: $35.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,484.92 |
| Travel and Lodging | $687.17 |
| Education | $35.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,465.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,177.92 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $1,155.84 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $927.21 | 2020-2025 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $726.25 | 2019-2025 | Jardiance |
| Amgen INC. | $726.14 | 2019-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $543.87 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $521.28 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $460.87 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $408.11 | 2023-2025 | |
| Ibsa Pharma INC. | $377.67 | 2020-2024 | Tirosint, Licart, Licart |
| Mannkind Corporation | $351.01 | 2021-2025 | Afrezza |
| Corcept Therapeutics | $340.17 | 2020-2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $320.37 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $313.37 | 2021-2025 | Gvoke Hypopen |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.43 | 2019-2024 | Cycloset |
| Alexion Pharmaceuticals, INC. | $268.74 | 2019-2025 | Strensiq |
| Antares Pharma, INC. | $268.21 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $241.36 | 2019-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $205.68 | 2023-2025 | Isturisa, Signifor Lar |
| Lifescan, INC. | $201.01 | 2019-2023 | |
| Insulet Corporation | $196.98 | 2020-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $189.78 | 2019-2022 | |
| Abbvie INC. | $187.41 | 2019-2025 | |
| Nevro Corp. | $175.85 | 2022-2024 | Senza |
| Amarin Pharma, INC. | $174.42 | 2019-2022 | |
| Beta Bionics, INC. | $166.31 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $156.56 | 2020-2025 | Tymlos |
| Astellas Pharma US INC | $117.25 | 2024-2025 | Veozah |
| Grt US Holding, INC. | $115.54 | 2022 | |
| Pfizer INC. | $113.11 | 2021-2023 | |
| Ascendis Pharma Endocrinology INC | $112.47 | 2025 | Yorvipath |
| Zealand Pharma US, INC. | $106.26 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $105.79 | 2025 | |
| Madrigal Pharmaceuticals | $94.33 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $92.50 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $58.99 | 2022-2024 | Crysvita |
| Horizon Therapeutics Plc | $55.22 | 2023 | Tepezza |
| Ipsen Biopharmaceuticals, INC | $53.01 | 2019-2020 | |
| Globus Medical, INC. | $49.56 | 2025 | Senza |
| Sequel Med Tech, LLC | $41.22 | 2025 | Twiist |
| Acerus Pharmaceuticals Corporation | $41.07 | 2020-2021 | |
| Kyowa Kirin, INC. | $40.79 | 2023-2024 | Crysvita |
| Vivus LLC | $38.26 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $38.18 | 2019-2024 | Evkeeza |
| Embecta Corp. | $33.28 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Arbor Pharmaceuticals, INC. | $32.47 | 2019-2020 | |
| Becton, Dickinson and Company | $32.40 | 2019 | |
| Esperion Therapeutics, INC. | $32.00 | 2021 | |
| Halozyme INC | $31.93 | 2023 | |
| Boston Scientific Corporation | $29.17 | 2025 | General - Pain Management |
| Verity Pharmaceuticals INC. | $22.48 | 2025 | Tlando |
| Averitas Pharma INC. | $22.15 | 2025 | Qutenza |
| Medtronic Minimed, INC. | $20.50 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.05 | 2020 | |
| Valeritas, INC. | $18.51 | 2019 | |
| Companion Medical, INC. | $17.57 | 2019 | |
| Avvisto Therapeutics, LLC | $15.77 | 2025 | Cycloset |
| Tolmar, INC. | $14.98 | 2024 | |
| Shire North American Group INC | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wenge Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.